Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Capone, L"'
Autor:
Gandhi AK; Celgene Corporation, Summit, New Jersey, USA, San Diego, California, USA. agandhi@celgene.com, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinoso L, Fang W, Xu S, Hampton G, Bartlett JB, Schafer P
Publikováno v:
Current cancer drug targets [Curr Cancer Drug Targets] 2010 Mar; Vol. 10 (2), pp. 155-67.
Autor:
Cicinelli, M. V., Rosenblatt, A., Grosso, D., Zollet, P., Capone, L., Rabiolo, A., Lattanzio, R., Loewenstein, A., Bandello, F., Nassisi, M., Tan, A., Reynolds, R., Singh, S. R., Vaezi, K. P., Giocanti-Aurégan, A., Weinberg, T., Faes, L., Schwartz, R., Reyes, D. Y. A., Savastano, A., Touhami, S., Garcia, H. R., Pohlmann, D., Plant, A., Ventura, C. V., Chatziralli, I., Phasukkijwatana, N., Ruiz-Medrano, J., Yuan, M., Yılmaz, İ., Vogt, D., Ting, D. S. W., Mustapha, M., Mendaro, M.
Publikováno v:
Eye (Lond)
BACKGROUND/OBJECTIVES: To investigate if the visual and anatomic response to the first dexamethasone implant (DEX) predicts the 12-month clinical outcome after shifting to fluocinolone acetonide (FAc) implant in patients with diabetic macular oedema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8b5788cd0cf19ece5d77cd762ff7baf
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099977516&doi=10.1038/s41433-020-01373-1&partnerID=40&md5=9c7ba461b3abfc1fadac86b2a3be37fc
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099977516&doi=10.1038/s41433-020-01373-1&partnerID=40&md5=9c7ba461b3abfc1fadac86b2a3be37fc